Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vuk Zdinjak

Jazz Pharma Building New State-Of-The-Art Facility For Cannabis-Based Research And Production

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and its subsidiary, GW Pharmaceuticals have begun construction of its new, state-of-the-art manufacturing facility at Kent Science Park (KSP) in Sittingbourne, UK, with an investment of over $100 million. 

The new facility, expected to be approximately 60,000 sq. ft, is designed to support the company's two regulatory-approved cannabis-based medicines, such as Epidiolex, and to support future capacity for new medicines under development.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.